---
title: Edwards Lifesciences (EW) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/ew
ticker: EW
as_of: 2026-10-17
sector: Healthcare
industry: Medical - Devices
---
# Edwards Lifesciences (EW)

Edwards Lifesciences (EW) closed at $86.60 on Oct 16, 2026, overvalued by 95% vs its model value of $44.31 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $86.60 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $44.31 |
| Price vs model | overvalued by 95% vs model |
| Range of that model | $31.20 – $85.45 |
| Market value | $49.9B |
| P/E (fiscal 2025) | 47.3 |
| Net margin (fiscal 2025) | 17.7% |
| Free cash flow (fiscal 2025) | $1.3B |
| Dividend yield (trailing twelve months) | 0.00% |
| Beta | 0.86 |
| Cost of capital (WACC) | 8.80% |
| Business classification | Mature & Stable (Low/slowing growth (~1% recent), Moderate margins (18% net margin), Highly cyclical earnings) |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $44.31 | $31.20 | $85.45 |
| DCF · Perpetuity growth · 10y | cross check | $50.12 | $35.51 | $95.41 |
| DCF · EBITDA exit · 5y | cross check | $111.69 | $92.58 | $133.88 |
| DCF · EBITDA exit · 10y | cross check | $110.68 | $85.95 | $142.67 |
| P/E · peers | cross check | $96.36 | $83.52 | $109.21 |
| P/E · own history | cross check | $84.78 | $69.15 | $106.37 |
| PEG | sanity check | $61.12 | $61.12 | $61.12 |
| EV/EBITDA · peers | cross check | $97.00 | $66.00 | $105.13 |
| EV/Revenue · peers | cross check | $102.85 | $91.10 | $156.71 |
| Earnings power value | cross check | $26.26 | $23.02 | $30.84 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

Past 90 days: 0 open-market buys ($0) and 11 open-market sales ($4.5M); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | Option/RSU exercise (10b5-1 plan) | 619 | $0 |
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | Open-market sell (10b5-1 plan) | 619 | $53,017.4 |
| Oct 8, 2026 | Lippis Daniel J. | CVP, TAVR | Option/RSU exercise (10b5-1 plan) | 619 | $44,988.9 |
| Sep 11, 2026 | Markowitz Wayne | CVP, JAPAC | Tax withholding | 355 | $30,803.4 |
| Sep 14, 2026 | Markowitz Wayne | CVP, JAPAC | Tax withholding | 568 | $47,922.2 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 28, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers | https://www.sec.gov/Archives/edgar/data/1099800/000109980026000048/ew-20260825.htm |
| Aug 4, 2026 | S-8 | Employee stock plan registration | https://www.sec.gov/Archives/edgar/data/1099800/000109980026000045/s-8ltsicp2026x08.htm |
| Aug 4, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1099800/000109980026000043/ew-20260630.htm |
| Jul 23, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1099800/000109980026000038/ew-20260723.htm |
| May 8, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 5.07 Submission of Matters to a Shareholder Vote; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1099800/000109980026000028/ew-20260507.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Bridgewater | 2026-06-30 | 275,279 | $24.9M |
| David Rolfe | 2026-06-30 | 165,208 | $14.9M |
| Torray | 2026-06-30 | 2,994 | $270,837 |

3 tracked managers in all.

## About

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascendin…

---

Source: https://sweetvaluelab.com/stocks/ew (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.